Clinical features of β-thalassemia and sickle cell disease

Patrick T. McGann, Alecia C. Nero, Russell E. Ware

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Sickle cell disease (SCD) and β-thalassemia are among the most common inherited diseases, affecting millions of persons globally. It is estimated that 5–7% of the world’s population is a carrier of a significant hemoglobin variant. Without early diagnosis followed by initiation of preventative and therapeutic care, both SCD and β-thalassemia result in significant morbidity and early mortality. Despite great strides in the understanding of the molecular basis and pathophysiology of these conditions, the burden of disease remains high, particularly in limited resource settings. Current therapy relies heavily upon the availability and safety of erythrocyte transfusions to treat acute and chronic complications of these conditions, but frequent transfusions results in significant iron overload, as well as challenges from acquired infections and alloimmunization. Hydroxyurea is a highly effective treatment for SCD but less so for β-thalassemia, and does not represent curative therapy. As technology and use of cellular and gene therapies expand, SCD and thalassemia should be among the highest disease priorities.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages1-26
Number of pages26
Volume1013
DOIs
StatePublished - 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1013
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Thalassemia
Sickle Cell Anemia
Erythrocyte Transfusion
Preventive Medicine
Iron Overload
Hydroxyurea
Therapeutics
Genetic Therapy
Early Diagnosis
Hemoglobins
Gene therapy
Technology
Morbidity
Safety
Mortality
Infection
Population
Iron
Availability

Keywords

  • Beta globin
  • Hemoglobin
  • Iron overload
  • Sickle cell disease
  • β-thalassemia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

McGann, P. T., Nero, A. C., & Ware, R. E. (2017). Clinical features of β-thalassemia and sickle cell disease. In Advances in Experimental Medicine and Biology (Vol. 1013, pp. 1-26). (Advances in Experimental Medicine and Biology; Vol. 1013). Springer New York LLC. https://doi.org/10.1007/978-1-4939-7299-9_1

Clinical features of β-thalassemia and sickle cell disease. / McGann, Patrick T.; Nero, Alecia C.; Ware, Russell E.

Advances in Experimental Medicine and Biology. Vol. 1013 Springer New York LLC, 2017. p. 1-26 (Advances in Experimental Medicine and Biology; Vol. 1013).

Research output: Chapter in Book/Report/Conference proceedingChapter

McGann, PT, Nero, AC & Ware, RE 2017, Clinical features of β-thalassemia and sickle cell disease. in Advances in Experimental Medicine and Biology. vol. 1013, Advances in Experimental Medicine and Biology, vol. 1013, Springer New York LLC, pp. 1-26. https://doi.org/10.1007/978-1-4939-7299-9_1
McGann PT, Nero AC, Ware RE. Clinical features of β-thalassemia and sickle cell disease. In Advances in Experimental Medicine and Biology. Vol. 1013. Springer New York LLC. 2017. p. 1-26. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4939-7299-9_1
McGann, Patrick T. ; Nero, Alecia C. ; Ware, Russell E. / Clinical features of β-thalassemia and sickle cell disease. Advances in Experimental Medicine and Biology. Vol. 1013 Springer New York LLC, 2017. pp. 1-26 (Advances in Experimental Medicine and Biology).
@inbook{9318e8495fb74b60922dcd83c8c2bcc6,
title = "Clinical features of β-thalassemia and sickle cell disease",
abstract = "Sickle cell disease (SCD) and β-thalassemia are among the most common inherited diseases, affecting millions of persons globally. It is estimated that 5–7{\%} of the world’s population is a carrier of a significant hemoglobin variant. Without early diagnosis followed by initiation of preventative and therapeutic care, both SCD and β-thalassemia result in significant morbidity and early mortality. Despite great strides in the understanding of the molecular basis and pathophysiology of these conditions, the burden of disease remains high, particularly in limited resource settings. Current therapy relies heavily upon the availability and safety of erythrocyte transfusions to treat acute and chronic complications of these conditions, but frequent transfusions results in significant iron overload, as well as challenges from acquired infections and alloimmunization. Hydroxyurea is a highly effective treatment for SCD but less so for β-thalassemia, and does not represent curative therapy. As technology and use of cellular and gene therapies expand, SCD and thalassemia should be among the highest disease priorities.",
keywords = "Beta globin, Hemoglobin, Iron overload, Sickle cell disease, β-thalassemia",
author = "McGann, {Patrick T.} and Nero, {Alecia C.} and Ware, {Russell E.}",
year = "2017",
doi = "10.1007/978-1-4939-7299-9_1",
language = "English (US)",
volume = "1013",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "1--26",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Clinical features of β-thalassemia and sickle cell disease

AU - McGann, Patrick T.

AU - Nero, Alecia C.

AU - Ware, Russell E.

PY - 2017

Y1 - 2017

N2 - Sickle cell disease (SCD) and β-thalassemia are among the most common inherited diseases, affecting millions of persons globally. It is estimated that 5–7% of the world’s population is a carrier of a significant hemoglobin variant. Without early diagnosis followed by initiation of preventative and therapeutic care, both SCD and β-thalassemia result in significant morbidity and early mortality. Despite great strides in the understanding of the molecular basis and pathophysiology of these conditions, the burden of disease remains high, particularly in limited resource settings. Current therapy relies heavily upon the availability and safety of erythrocyte transfusions to treat acute and chronic complications of these conditions, but frequent transfusions results in significant iron overload, as well as challenges from acquired infections and alloimmunization. Hydroxyurea is a highly effective treatment for SCD but less so for β-thalassemia, and does not represent curative therapy. As technology and use of cellular and gene therapies expand, SCD and thalassemia should be among the highest disease priorities.

AB - Sickle cell disease (SCD) and β-thalassemia are among the most common inherited diseases, affecting millions of persons globally. It is estimated that 5–7% of the world’s population is a carrier of a significant hemoglobin variant. Without early diagnosis followed by initiation of preventative and therapeutic care, both SCD and β-thalassemia result in significant morbidity and early mortality. Despite great strides in the understanding of the molecular basis and pathophysiology of these conditions, the burden of disease remains high, particularly in limited resource settings. Current therapy relies heavily upon the availability and safety of erythrocyte transfusions to treat acute and chronic complications of these conditions, but frequent transfusions results in significant iron overload, as well as challenges from acquired infections and alloimmunization. Hydroxyurea is a highly effective treatment for SCD but less so for β-thalassemia, and does not represent curative therapy. As technology and use of cellular and gene therapies expand, SCD and thalassemia should be among the highest disease priorities.

KW - Beta globin

KW - Hemoglobin

KW - Iron overload

KW - Sickle cell disease

KW - β-thalassemia

UR - http://www.scopus.com/inward/record.url?scp=85033689456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033689456&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7299-9_1

DO - 10.1007/978-1-4939-7299-9_1

M3 - Chapter

C2 - 29127675

AN - SCOPUS:85033689456

VL - 1013

T3 - Advances in Experimental Medicine and Biology

SP - 1

EP - 26

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -